Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 Trap in Adult Autoinflammatory Diseases
NCT00094900Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Oct 2004
- Primary completion
- Sep 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of rilonacept in neonatal-onset multisystem inflammatory disease (NOMID), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), Familial Mediterranean fever (FMF), adult-onset Still's disease (AOSD), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Oct 2004; status: completed.
02
Drugs
rilonacept
03
Conditions
neonatal-onset multisystem inflammatory disease (NOMID)Muckle-Wells syndrome (MWS)familial cold autoinflammatory syndrome (FCAS)Familial Mediterranean fever (FMF)adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT00094900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094900.